Covid-19
New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic.
23 Jun, 2021 | 10:22h | UTCNews release: New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic – Harvard Medical School
Original Study: Assessing the Association Between Social Gatherings and COVID-19 Risk Using Birthdays – JAMA Internal Medicine
Commentary on Twitter (thread – click for more)
The link between birthdays and Covid-19
Thread on our new study (w/ @CM_Whaley, Jon Cantor, Megan Pera) in @JAMAInternalMed
Using data on ~3M households, households in which a member had bday 2 wks prior were ~30% more likely to have a covid diagnosishttps://t.co/KHCvGAlvox
— Anupam Jena (@AnupamBJena) June 21, 2021
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach.
23 Jun, 2021 | 10:23h | UTC
[Preprint] Rapid displacement of SARS-CoV-2 variant B.1.1.7 (Alpha) by B.1.617.2 (Delta) and P.1 (Gamma) in the United States.
22 Jun, 2021 | 10:12h | UTCRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Commentary on Twitter
🆕💥💥Preprint
📌B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
📌B.1.617.2 will soon be the dominant variant in the US
📌B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) June 22, 2021
Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
22 Jun, 2021 | 10:08h | UTCIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Perspective | COVID-19: The rise and rise of Delta.
22 Jun, 2021 | 10:10h | UTCCOVID-19: The rise and rise of Delta – Sciblogs
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
22 Jun, 2021 | 10:04h | UTC
Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
21 Jun, 2021 | 08:55h | UTC
Commentary on Twitter
NEW publication in Eurosurveillance
Increased transmissibility & global spread of #SARSCoV2 VOC & VOI
Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)
⬇️https://t.co/pmyfQMM78y pic.twitter.com/Xz3cOImRvc
— Maria Van Kerkhove (@mvankerkhove) June 17, 2021
National surveillance in England showed low risk of reinfection with Covid-19 – “There were 15,893 possible reinfections with SARS-CoV-2 identified up to 30 May 2021 in England throughout the pandemic, out of nearly 4 million people with confirmed infections. This is equivalent to around 0.4% cases becoming reinfected”.
21 Jun, 2021 | 08:56h | UTCNew national surveillance of possible COVID-19 reinfection, published by PHE – Public Health England
Related: Had COVID? You’ll probably make antibodies for a lifetime – Nature AND COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds. AND Study shows low risk of SARS-CoV-2 reinfection 1 year after primary infection.
WHO says delta is becoming the dominant Covid variant globally.
21 Jun, 2021 | 08:54h | UTCWHO says delta is becoming the dominant Covid variant globally – CNBC
Perspective | A beautiful idea: how COVAX has fallen short.
21 Jun, 2021 | 08:52h | UTCA beautiful idea: how COVAX has fallen short – The Lancet
Commentaries on Twitter
#COVAX was meant to supply #COVID19 vaccines for all based on solidarity and equity. Instead, it relies on rich countries' willingness to share their doses—Ann Danaiya Usher tracks the ambitions and shortcomings of COVAX: https://t.co/FbAZ1D8M4j #VaccinEquity pic.twitter.com/q880pzeU1s
— The Lancet (@TheLancet) June 19, 2021
#Vaccine doses given/100 inhabitants…🤔Rich countries praising solidarity by contributing to #COVAX while making sure that there is barely any #COVID19 vaccine left to be purchased through covax.
Check also @newhumanitarian: https://t.co/K1zzM6O3on pic.twitter.com/IpH0mDJqwC
— Tim Buder (@Tim_Buder) February 10, 2021
“COVAX has delivered over 72m doses to 125 countries. But that is far less than 172m it should have delivered by now. Of the 2.1 billion COVID-19 vaccine doses administered worldwide so far, COVAX has been responsible for less than 4%"#PeoplesVaccinehttps://t.co/TZKc8YPAdJ
— Steve Jackson 💙 (@SteJck) June 20, 2021
M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19.
21 Jun, 2021 | 08:45h | UTC
Study: Sperm parameters not changed before and after COVID-19 mRNA vaccination.
21 Jun, 2021 | 08:50h | UTCSperm Parameters Before and After COVID-19 mRNA Vaccination – JAMA
Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.
21 Jun, 2021 | 08:48h | UTC
Perspective | Sewage sleuths helped an Arizona town beat back Covid-19. For wastewater epidemiology, that’s just the start.
21 Jun, 2021 | 08:43h | UTCRelated: The myriad ways sewage surveillance is helping fight COVID around the world – Nature AND Testing sewage can give school districts, campuses and businesses a heads-up on the spread of COVID-19 – The Conversation AND It’s time to begin a national wastewater testing program for Covid-19 – STAT AND Coronavirus: Testing sewage an ‘easy win’ – BBC
Perspective | Human waste could be the next big weapon in controlling COVID-19.
21 Jun, 2021 | 08:42h | UTCHuman Waste Could Be The Next Big Weapon in Controlling COVID-19 – TIME
Related: The myriad ways sewage surveillance is helping fight COVID around the world – Nature AND Testing sewage can give school districts, campuses and businesses a heads-up on the spread of COVID-19 – The Conversation AND It’s time to begin a national wastewater testing program for Covid-19 – STAT AND Coronavirus: Testing sewage an ‘easy win’ – BBC
Africa’s COVID-19 surge is expected to worsen, warns WHO.
21 Jun, 2021 | 08:44h | UTCAfrica’s COVID-19 Surge is Expected to Worsen, Warns WHO – Health Policy Watch
Audio Interview: potential treatments for children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19.
18 Jun, 2021 | 08:33h | UTCAudio Interview: Covid-19 in Children – New England Journal of Medicine
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.
18 Jun, 2021 | 08:35h | UTCEditorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.
18 Jun, 2021 | 08:36h | UTCTreatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine
Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Commentaries: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London AND Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre
Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.
18 Jun, 2021 | 08:29h | UTCCausation or confounding: why controls are critical for characterizing long COVID – Nature
Dr. Fauci says the risks from the Delta variant underscore the importance of vaccines.
18 Jun, 2021 | 08:31h | UTCDr. Fauci Says The Risks From The Delta Variant Underscore The Importance Of Vaccines – NPR
Cohort study: swallowing and voice outcomes in patients hospitalized with COVID-19.
18 Jun, 2021 | 08:24h | UTCRelated study: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One
ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.
18 Jun, 2021 | 08:26h | UTC
COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds.
18 Jun, 2021 | 08:27h | UTCOriginal study: Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing – Clinical Infectious Diseases
[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.
17 Jun, 2021 | 09:55h | UTCOriginal study (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Commentaries: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science AND Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP AND Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT AND Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Commentary on Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021